Controversial lab studies that modify bird flu viruses in ways that could make them riskier to humans will soon resume after being on hold for more than 4 years.
Assessing the potential GoF risks on engineered fast-growing microbes does not lead to a clear outcome that can be applied to all types of engineered fast-growing strains.
In December 2017, the US Department Health and Human Services (HHS) issued its policy on the oversight of research involving enhanced potential pandemic pathogens.
This paper discusses the risks and ethical issues surrounding gain of funtion researech.
The US National Institutes of Health (NIH) is lifting a funding pause dating back to October 2014 on gain-of-function (GOF) experiments involving influenza, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS) viruses.
Many viruses change constantly and occasionally they undergo dramatic changes that can cause local or global outbreaks.
A Professor of Microbiology and Immunology at Columbia University discussed gain-of function experiments.
Officials have released a plan to help US agencies decide whether to fund research studies that make viruses more dangerous.
An analysis intended to inform National Science Advisory Board for Biosecurity’s (NSABB)recommendations about a conceptual approach to the evaluation of Gain of Function (GoF) studies, and for the US government to create policy regarding GoF research.